Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a confirmed diagnosis of relapsing multiple sclerosis (RMS), as defined by McDonald criteria 1 through 4 (Polman, 2005)~* Must have an EDSS score between 0.0 and 5.0.~* Must have experienced at least 2 relapses that have been medically documented within the last 3 years with at least one occurring in the last 12 months~Key Exclusion Criteria:~* Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease~* Pregnant or nursing women~* Prior treatment with interferon could not exceed 4 weeks and subjects must have discontinued interferon treatment 6 months prior to Baseline~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every 2 weeks for 48 weeks followed by 125 µg peginterferon beta-1a subcutaneously every 2 or 4 weeks for 48 weeks.
- Peginterferon Beta-1a Q2W (Type: EXPERIMENTAL): 125 µg peginterferon beta-1a subcutaneously every 2 weeks (Q2W) for 96 weeks.
- Peginterferon Beta-1a Q4W (Type: EXPERIMENTAL): 125 µg peginterferon beta-1a subcutaneously every 4 weeks (Q4W) for 96 weeks. Participants received a placebo injection 2 weeks after each active injection (in order to maintain the blind with Q2W arm).

Based on this trial design, predict the completion outcome and termination type (if applicable).